Tarsus Pharmaceuticals, Inc. (TARS) Profit Margins
Over the twelve months to 2026-06-30, Tarsus Pharmaceuticals, Inc. (TARS) had gross margin 93.3%, operating margin -8.0%, net margin -7.7%, free cash flow margin 9.2%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TARSTarsus Pharmaceuticals, Inc.Follow TARS — free
—
Price chart with a free account
- Market cap
- 3.0B
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Gross margin | — | 96.3% | 90.9% | 93.0% | 93.2% | 93.3% | |
| Operating margin | -21.3% | -242.9% | -820.5% | -65.9% | -15.7% | -8.0% | |
| Net margin | -24.2% | -240.5% | -778.9% | -63.2% | -14.7% | -7.7% | |
| FCF margin | 5.5% | -191.9% | -682.0% | -46.2% | -4.9% | 9.2% |
USD millions · SEC XBRL
Tarsus Pharmaceuticals, Inc. — questions
- What is Tarsus Pharmaceuticals, Inc.'s gross margin?
- 93.3% over the twelve months to 2026-06-30.
- What is Tarsus Pharmaceuticals, Inc.'s operating margin?
- -8.0% over the twelve months to 2026-06-30.
- What is Tarsus Pharmaceuticals, Inc.'s net profit margin?
- -7.7% over the twelve months to 2026-06-30.
Every figure on this page comes from Tarsus Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.